TRACT Therapeutics is a pioneering brand that is revolutionizing transplant medicine through its groundbreaking personalized cellular product. By reducing or even eliminating the necessity for immunosuppressive drug therapy, TRACT Therapeutics is transforming the therapeutic approach to ensure the long-term stability of transplanted organs and dramatically enhance the lives of transplant recipients. Additionally, their innovative T-cell therapy has the potential to treat various autoimmune diseases, including inflammatory bowel disease, rheumatoid arthritis, and multiple sclerosis.

The company was founded by Dr. Leventhal, a renowned expert in the field of regulatory T cells, who has dedicated over 25 years to researching and developing new treatments in transplant medicine. Driven by the desire to find a solution that would allow transplanted organs to function optimally without the detrimental side effects of anti-rejection drugs, Dr.

Leventhal and his team discovered a way to isolate and expand a patient's own regulatory T immune cells. By infusing these cells into the patient's body after a transplant, TRACT Therapeutics empowers patients to regulate their immune systems, drastically reducing the need for immunosuppressive drugs. With a team of scientific advisors and technology experts, TRACT Therapeutics is committed to the realization of Dr.

Leventhal's vision of immune tolerance. Their mission is to create a regulatory pathway, develop a commercialization plan, and introduce this breakthrough therapy to patients. Through their dedication to scientific, medical, and commercial success, TRACT Therapeutics is transforming the future of transplant medicine